Title	Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones
Author(s)	Kongsoi, Siriporn; Yokoyama, Kazumasa; Suprasert, Apinun; Utrarachkij, Fuangfa; Nakajima, Chie; Suthienkul, Orasa; Suzuki, Yasuhiko
Citation	Drug Testing and Analysis, 7(8), 714-720 https://doi.org/10.1002/dta.1744
Issue Date	2015-08
Doc URL	http://hdl.handle.net/2115/76491
Rights	This is the peer reviewed version of the following article: Siriporn Kongsoi, Kazumasa Yokoyama, Apinun Suprasert, Fuangfa Utrarachkij, Chie Nakajima, Orasa Suthienkul, Yasuhiko Suzuki. Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones. Drug Test Anal. 2015;7:714-720, which has been published in final form at https://doi.org/10.1002/dta.1744 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Type	article (author version)
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	Siriporn_Revision_For Drug Testing and Analysis_2014.10.02_Accepted.pdf

[Instructions for use](#)

Characterization of *Salmonella* Typhimurium DNA Gyrase as a Target of Quinolones

Siriporn Kongsoi,¹ Kazumasa Yokoyama,² Apinun Suprasert,³ Fuangfa Utrarachkij,⁴

Chie Nakajima,^{1, 5} Orasa Suthienkul,^{4, *} and Yasuhiko Suzuki^{1, 5, *}

¹ Division of Bioresources, Hokkaido University Research Center for Zoonosis Control,
Sapporo 001-0020, Japan

² Central Research Laboratory, Kissei Pharmaceutical Co., Ltd, Nagano, Japan

³ Department of Anatomy, Faculty of Veterinary Medicine, Kasetsart University, Bangkok,
Thailand

⁴ Department of Microbiology, Faculty of Public Health, Mahidol University, Bangkok,
Thailand

⁵ Hokkaido University The Global station for Zoonosis Control, Sapporo, Japan

Running title: *Salmonella* Typhimurium DNA Gyrase and Quinolones

***Corresponding authors:**

Yasuhiko Suzuki: Mailing address: Division of Global Epidemiology, Hokkaido University
Research Center for Zoonosis Control, Kita 20-Nishi 10, Kita-ku, Sapporo 001-0020, Japan.
Phone: 81-11-706-9503. Fax: 81-11-706-7310. E-mail: suzuki@czc.hokudai.ac.jp.

Orasa Suthienkul: Mailing address: Department of Microbiology, Faculty of Public Health,
Mahidol University, 420/1 Rajavithi Road, Rachathewi Bangkok 10400 Thailand.

Phone: +662-354-8354. E-mail: orasa.sut@mahidol.ac.th.

ABSTRACT

Quinolones exhibit good antibacterial activity against *Salmonella* spp. isolates and are often the choice of treatment for life-threatening salmonellosis due to multi-drug resistant strains. To assess the properties of quinolones, we performed an *in vitro* assay to study the antibacterial activities of quinolones against recombinant DNA gyrase. We expressed the *S. Typhimurium* DNA gyrase A (GyrA) and B (GyrB) subunits in *Escherichia coli*. GyrA and GyrB were obtained at high purity (>95%) by nickel-nitrilotriacetic acid agarose resin column chromatography as His-tagged 97-kDa and 89-kDa proteins, respectively. Both subunits were shown to reconstitute an ATP-dependent DNA supercoiling activity. Drug concentrations that suppressed DNA supercoiling by 50% (IC₅₀s) or generated DNA cleavage by 25% (CC₂₅s) demonstrated that quinolones highly active against *S. Typhimurium* DNA gyrase share a fluorine atom at C-6. The relationships between the minimum inhibitory concentrations (MICs), IC₅₀s and CC₂₅s were assessed by estimating a linear regression between two components. MICs measured against *S. Typhimurium* NBRC 13245 correlated better with IC₅₀s (R = 0.9988) than CC₂₅s (R = 0.9685). These findings suggest that the DNA supercoiling inhibition assay may be a useful screening test to identify quinolones with promising activity against *S. Typhimurium*. The quinolone structure-activity relationship demonstrated here shows that C-8, the C-7 ring, the C-6 fluorine, and N-1 cyclopropyl substituents are desirable structural features in targeting *S. Typhimurium* gyrase.

Key words: DNA gyrase/Quinolones/*Salmonella Typhimurium*

INTRODUCTION

Non-typhoidal *Salmonella* is the primary foodborne zoonotic agent of salmonellosis in many countries. The global impact of non-typhoidal *Salmonella* on human health is high, with an estimated 94 million cases and 155,000 deaths each year, of which 80 million are believed to be foodborne [1]. According to the World Health Organization, in most countries participating in the Global Foodborne Infections Network, *Salmonella* serovar Enteritidis and *Salmonella* serovar Typhimurium are the most frequently isolated serotypes of *Salmonella* [2]. Gastroenteritis caused by *Salmonella* is generally a self-limited illness. However, antimicrobials may be required to treat invasive cases and susceptible groups such as young children, the elderly and immunocompromised patients [3]. In general, chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole are used to treat salmonellosis, but resistance to these drugs has increased significantly in recent years [4–6]. In the case of invasive and systemic salmonellosis in humans and animals, quinolones are the preferred drugs for treatment.

DNA gyrases and DNA topoisomerase IV are essential enzymes for the maintenance of chromosomal metabolism in bacteria, and DNA gyrase is known to be the primary target of quinolones in salmonellae. This is due to most amino acid substitutions conferring quinolone resistance being found in DNA gyrase, but not in topoisomerase IV [7–9]. Mutations conferring quinolones resistance are mostly located in a region of the *gyrA* gene specifying the N-terminal domain portion, known as the quinolone resistance-determining region (QRDR) [10]. It has been proposed that the quinolone-binding pocket (QBP) is a site surrounded by surfaces involving the QRDR of both GyrA and GyrB proteins [11,12]. The mechanisms of the interaction between quinolones, drugs, DNA and gyrases remain unclear. Elucidating this information would help to improve existing and design new drugs for the treatment of salmonellosis.

The aim of this work was to further investigate the *in vitro* antibacterial activity of quinolones against *Salmonella* DNA gyrases and to establish a more complete model of the wild-type (WT) gyrase-quinolone interaction. To that end, we assessed the potency of 10 quinolones with quinolone-inhibited supercoiling and quinolone-mediated DNA cleavage assays.

MATERIALS AND METHODS

Reagents and kits. Ciprofloxacin (CIP), enrofloxacin (ENR), gatifloxacin (GAT), levofloxacin (LVX), ofloxacin (OFX) and sparfloxacin (SPX) were purchased from LKT Laboratories, Inc. (St. Paul, MN, USA). Oxolinic acid (OXO) and nalidixic acid (NAL) were purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan). Moxifloxacin (MXF) was obtained from Toronto Research Chemical Inc. (Toronto, Ontario, Canada). Sitafloxacin (SIT) was a gift from Daiichi-Sankyo Pharmaceutical, Co., Ltd. (Tokyo, Japan). Oligonucleotide primers were synthesized by Life Technologies (Carlsbad, CA, USA). TaKaRa Mighty (Blunt End) Cloning Reagent Set (pUC118) and Ni-nitrilotriacetic acid protein purification kits were purchased from Life Technologies. Restriction enzymes were obtained from New England Biolabs, Inc. (Ipswich, MA, USA). Relaxed pBR322 DNA was purchased from John Innes Enterprises Ltd. (Norwich, United Kingdom). Protease inhibitor cocktail (Complete Mini, EDTA-free) was purchased from Roche Applied Science (Mannheim, Germany).

Bacterial strains and plasmids. *S. Typhimurium* (strain LT2 / NBRC 13245) was purchased from NITE Biological Resource Center (Chiba, Japan). *E. coli* strain TOP-10 (Life Technologies) was used as the host for cloning purposes. *E. coli* strain BL21(DE3)/pLysS was purchased from Merck KGaA (Darmstadt, Germany) and used for protein expression. The vector plasmid pET-20b (+) was used to construct expression plasmids for the *S. Typhimurium* proteins, GyrA and GyrB.

Determination of minimum inhibitory concentration (MICs). *S. Typhimurium* NBRC 13245 was analyzed for antimicrobial resistance patterns using the broth microdilution method based on guidelines established by the US National Committee on Clinical Laboratory Standards (NCCLS) [13]. An adjusted bacterial inoculum (10^6 CFU/ml/10 μ l/well) was added to each well of a sterile U-based microtitre plate containing the test concentrations of quinolones (90 μ l/well). Consequently, a 5×10^5 CFU/ml concentration from the last inoculum was obtained in each well, and this plate was incubated for 18 hours at 37°C. The MIC was defined as the lowest antibiotic concentrations that inhibited visible bacterial growth after incubation. The panel of antimicrobial agents was CIP, ENR, GAT, LVX, OFX, SPX, OXO, NAL, MXF and SIT.

Construction of wild-type (WT) DNA gyrase expression vectors. DNA fragments, including *gyrA* and *gyrB*, were amplified from *S. Typhimurium* NBRC 13245 DNA by polymerase chain reaction (PCR) using the primers listed in Table 1. Two pairs of primers, ST1/ST2 and ST8/ST9, were used to amplify the complete *gyrA* and *gyrB* genes, respectively. *Nde* I restriction sites (CATATG) were included as overlaps of the ATG initiation codons for *gyrA* (ST1) and *gyrB* (ST8) primers, and the *Xho* I site (CTCGAG) was included after the stop codons for the *gyrA* (ST2) and *gyrB* (ST9) primers. PCR products corresponding to the 2.6-kb *gyrA* and 2.4-kb *gyrB* genes were ligated into the blunt-ended cloning plasmid, transformed into *E. coli* TOP-10, and plated on Luria-Bertani (LB) agar containing ampicillin (100 μ g ml⁻¹). The *gyrA* and *gyrB* cassettes were digested with *Nde* I and *Xho* I, ligated into pET-20b (+) digested with the same restriction endonucleases, and transformed into *E. coli* TOP-10 to obtain GyrA and GyrB expression plasmids. Recombinant clones were selected from the resistant colonies on LB agar plates containing ampicillin (100 μ g ml⁻¹).

Expression and purification of recombinant DNA gyrase. DNA gyrase subunits were purified as previously described [14–16]. Expression plasmids carrying the WT *gyrA* and WT

gyrB genes of *S. Typhimurium* were transformed into *E. coli* BL21(DE3)/pLysS. GyrA and GyrB expression was induced with the addition of 1 mM isopropyl- β -D-thiogalactopyranoside (Wako Pure Chemical Industries Ltd., Tokyo, Japan), followed by further incubation at 18°C for 13 h. Recombinant DNA gyrase subunits in the supernatant of the sonicated lysate (by Sonifier 250; Branson, Danbury, CT, USA) were purified by nickel-nitrilotriacetic acid (Ni-NTA) agarose resin column chromatography (Life Technologies Corp.). Protein fractions were examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After purification, the protein fractions were added by glycerol to yield 50% (wt/vol) and stored at -80°C until use.

DNA supercoiling activities and inhibition by quinolones. ATP-dependent and quinolone-inhibited DNA supercoiling assays were carried out as previously described [14–16] with the following modifications. The reaction mixture (total volume, 30 μ l) consisted of DNA gyrase assay buffer, relaxed pBR322 DNA (0.3 μ g), and GyrA and GyrB proteins (3 μ M each). Reactions were run at 35°C for 20 min and stopped by the addition of 30 μ l of chloroform-isoamyl alcohol (24:1 mixture, v/v) and 3 μ l of 10X DNA loading dye. The total reaction mixtures were subjected to electrophoresis using a 1% agarose gel in 0.5X Tris-borate-EDTA (TBE) buffer. The gels were run for 60 min at 80 mA and stained with ethidium bromide (0.7 μ g ml⁻¹). Supercoiling activity was evaluated by tracing the brightness of the bands with the software ImageJ (<http://rsbweb.nih.gov/ij>). The inhibitory effect of FQs on DNA gyrases was assessed by determining the drug concentrations required to inhibit the supercoiling activity of the enzyme by 50% (IC₅₀s) in the presence or absence of 2-fold serial dilutions in the concentrations of 10 quinolones. To allow direct comparisons, all incubations with DNA gyrase were carried out and processed in parallel on the same day under identical conditions. All enzyme assays were performed at least three times to confirm reproducibility.

Quinolone-mediated DNA cleavage assay. Quinolone-mediated DNA cleavage assays were

carried out as previously described [14–16]. Supercoiled, rather than relaxed, pBR322 DNA was used as the substrate for cleavage assays. The reaction mixture (total volume, 30 μ l) contained DNA gyrase assay buffer, purified GyrA and GyrB (3 μ M each), supercoiled pBR322 DNA (0.3 μ g) and 2-fold serially diluted concentrations of ten quinolones. After incubation for 20 min at 35°C, 3 μ l of 2% SDS and 3 μ l of proteinase K (1 mg ml⁻¹) were added to the reaction mixture. After additional incubation for 30 min at 35°C, reactions were stopped to allow a relaxation activity by the addition of 3 μ l of 0.5 mM EDTA, 30 μ l chloroform-isoamyl alcohol (24:1 mixture, v/v) and 3 μ l of 10 $\times$ DNA loading dye. The plasmid pBR322 linearized by *Bam*HI digestion was used as a marker for cleaved DNA. The total reaction mixtures were subjected to electrophoresis using 0.8% agarose gels in 0.5 $\times$ TBE buffer. The gels were run for 60 min at 80 mA, stained with ethidium bromide (0.7 μ g ml⁻¹) and photographed under UV transillumination. The extent of DNA cleavage was quantified with the Molecular Analyst software ImageJ (<http://rsbweb.nih.gov/ij>). The quinolone concentrations required to induce 25% of the maximum DNA cleavage (CC₂₅s) were determined for the 10 quinolones.

Correlation between MICs, IC₅₀s and CC₂₅s against *S. Typhimurium* gyrases. The relationships between the MICs, IC₅₀s and CC₂₅s were converted to log₁₀ and assessed by estimating a linear regression between two components,. The strength of this relationship was quantified by the R coefficient and displayed graphically by the regression line and the two curves defining the 95% confidence interval for this regression.

RESULTS

Quinolone susceptibility patterns. The MICs of quinolones and fluoroquinolones were determined against *S. Typhimurium* NBRC 13245 (Table 2). The MICs of fluoroquinolones GAT, SPX, LVX, MXF, ENR, OFX, CIP and SIT were 64- to 512-fold lower than those of

quinolones OXO and NAL

Expression and purification of recombinant GyrA and B proteins. Ni-nitrilotriacetic acid affinity purification from 200 ml cultures resulted in 16 and 1.6 mg of soluble His-tagged 97-kDa and 89-kDa proteins, respectively, corresponding to GyrA and GyrB (Figure 1). Both recombinant subunits were obtained at high purity (>95%).

DNA supercoiling activity of recombinant DNA gyrase. Combinations of GyrA and GyrB were examined for DNA supercoiling activity. A combination of GyrA and GyrB at 3 μ M each in the presence of ATP was sufficient for the conversion of 100% of 0.3 μ g of relaxed plasmid pBR322 DNA to its supercoiled form and was used for all DNA supercoiling experiments. No subunit alone exhibited DNA supercoiling activity in the presence of 1 mM ATP, and no supercoiling activity was observed when ATP was absent from the reaction mixture, which indicated the lack of or low concentration of *E. coli*-derived DNA gyrase subunits (Figure 2).

IC₅₀s of quinolones. The inhibitory effects of quinolones including CIP, ENR, GAT, LVX, OFX, SPX, MXF, SIT, OXO and NAL on the *S. Typhimurium* gyrase were elucidated by the quinolone-inhibited DNA supercoiling assay. A set of representative results showing the inhibitory effect of CIP and NAL is shown in Figure 3, and the results for the other quinolones are presented in Figure S1. Each quinolone showed dose-dependent inhibition, with IC₅₀s ranging from 0.22 to 65.1 μ g ml⁻¹. The inhibitory effects of quinolones against the recombinant gyrase are presented as IC₅₀s in ascending order in Table 2. A good correlation was found between the IC₅₀ values and the corresponding MICs, as shown in Figure 5 (correlation coefficient values, R = 0.9988).

CC₂₅s of quinolones. To examine the effects of quinolones on the cleavable-complex formation by the recombinant DNA gyrases, quinolone-mediated DNA cleavage assays were carried out in which supercoiled pBR322 was incubated with recombinant GyrA and GyrB in

the presence or absence of increasing concentrations of quinolones. Figure 4 shows the results of a representative quinolone-mediated DNA cleavage assay using CIP and NAL, and those for the other quinolones are presented in Figure S2. Table 2 presents the CC₂₅s of the ten quinolones, in which each quinolone showed dose-dependent inhibition, with CC₂₅s ranging from 0.24 to 8.64 µg ml⁻¹ (Table 2). A good correlation was found between the CC₂₅ values and the corresponding MICs, as shown in Figure 6 (correlation coefficient values, R = 0.9685).

DISCUSSION

The incidence of human non-typhoidal *Salmonella* infections has been increasing in many countries, and the emergence of quinolone-resistant *Salmonella* strains is a serious concern because this class of antibacterial agents constitutes the treatment of choice in cases of acute salmonellosis caused by multidrug-resistant strains. Although the main target of quinolones is known to be DNA gyrase, the molecular details of quinolone-DNA gyrase interactions have not been elucidated in *Salmonella*. Hence, based on previous studies [14–16], we produced the His-tagged GyrA and GyrB of *S. Typhimurium* and obtained an adequate amount of functional *S. Typhimurium* DNA gyrase after reconstitution. The ability of reconstituted enzymes to convert the relaxed form pBR322 plasmid DNA to the supercoiled form allowed us to examine and compare the inhibitory effects of 10 quinolones using the quinolone-inhibited DNA supercoiling assay and quinolone-mediated DNA cleavage assay. The DNA gyrase supercoiling inhibition assay and quinolone-mediated DNA cleavage assay are distinct in that the former is a measure of catalytic inhibition, whereas the latter probes an established equilibrium between the ternary DNA gyrase-drug complexes in which the DNA is either broken or intact [17,18].

Quinolones inhibited the DNA supercoiling activity of *S. Typhimurium* DNA gyrase

in a dose-dependent manner (Fig. 3 and Supplementary Fig. 1), as it has been reported for other bacteria [19–23]. Among the ten quinolones examined, eight fluoroquinolones exhibited high inhibitory activity against *S. Typhimurium* DNA gyrase with IC_{50} s below $1\ \mu\text{g}\ \text{ml}^{-1}$, in contrast to two quinolones OXO and NAL whose IC_{50} s were 4.93 and $65.1\ \mu\text{g}\ \text{ml}^{-1}$, respectively (Table 2). Similar results were observed in the quinolone-mediated DNA cleavage assay. Eight fluoroquinolones exhibited high activity to mediate DNA cleavage with CC_{25} s below $1\ \mu\text{g}\ \text{ml}^{-1}$, while the two quinolones without fluorine at position 6 had lower activities (Table 2). Analysis of the quinolone structure-activity relationship showed that the eight fluoroquinolones shared certain structural features. Position 1 is the part of the enzyme-DNA binding complex, and has a hydrophobic interaction with the major groove of DNA [24]. A cyclopropyl substituent is now considered the most potent modification here. Another structure at this position is found in OFX and LVX which has a fused ring between position 1 and 8. Position 7 is one of the most influential points on the molecule, and the presence of a five- or six-membered nitrogen heterocycle at this position has been reported to improve the molecule's activity and pharmacokinetic profile [25]. The most common heterocycles employed at position 7 are aminopyrrolidines and piperazines. The addition of azabicyclo to position 7 has resulted in MXF with significant anti-Gram-positive activity and marked lipophilicity [26].

DNA gyrase is a type II topoisomerase and an essential enzyme for DNA supercoiling, which is required for DNA replication and gene transcription. A domain of the N-terminal part of the A subunit of DNA gyrase is highly conserved among prokaryotes. In addition, the amino acid residues from the positions 67 to 106 of the A subunit in the numbering system used in *E. coli* was defined as the QRDR [27], which is supposed to be the site of interaction between the A subunit of gyrase and quinolones. The *S. Typhimurium* QRDR sequence of GyrA was compared with 4 bacterial species (Fig. 7). The results of the quinolone structure-

activity relationship analysis based on the *S. Typhimurium* WT QRDR sequence were highly concordant with those based on the *E. coli* WT QRDR sequence, which has a 100% identical QRDR sequence with *S. Typhimurium* (Fig. 7). As summarized in Table 3, IC₅₀s of quinolones against *S. Typhimurium* and *E. coli* [28] WT DNA gyrase were lower than those against *Mycobacterium tuberculosis* [22], *Streptococcus pneumoniae* [29] and *Mycoplasma pneumoniae* [23]. This result suggested that the interaction of quinolones with *S. Typhimurium* and *E. coli* WT DNA gyrase are stronger than those from other bacterial species. An early study by Guillemin *et al.* [30] proposed that the amino acid residue at position 83 in GyrA played a key role in the intrinsic susceptibility of DNA gyrases to quinolones in mycobacteria. In their study, the serine residue and alanine residue correlated with low and high MICs, respectively. As shown in Figure 7, the amino acid at position 83 in *S. Typhimurium* and *E. coli* DNA gyrase (exhibited by arrowhead) was serine, while those at equivalent positions in DNA gyrase of *M. tuberculosis*, *S. pneumoniae* and *M. pneumoniae* were alanine, serine and methionine, respectively. The findings by Guillemin *et al.* agree in part with our current observation. The amino acid residue at position 83 may be the cause of the intrinsic susceptibility of WT DNA gyrases to quinolones in *M. tuberculosis* and *M. pneumoniae* but not in *S. pneumoniae*. ClastalW analysis demonstrated a strong similarity in the QRDR amino acid sequence QRDR of WT GyrA beyond the genus (Fig. 7), a similarity that was a critical point for the wide spectrum of quinolones. However, the amino acids in the QRDR that are distinct between bacterial species may contribute to various intrinsic susceptibilities; nevertheless, amino acid residues outside of QRDR also need to be considered.

The IC₅₀s of the *S. Typhimurium* DNA gyrase correlated well with MICs, confirming their ability to inhibit the growth of *S. Typhimurium* (R = 0.999). However, the IC₅₀s and MICs were not proportional; for example, sitafloxacin and ciprofloxacin MICs were about

30-fold higher than in the gyrase assay. This nonproportionality has been noted by others [31] and presumably reflects basic differences in the cell-permeability properties and accumulation of the different quinolones [32]. In the quinolone-mediated DNA cleavage assay, the effective quinolone concentrations were slightly different from those inhibiting supercoiling and less correlated with those inhibiting *S. Typhimurium* growth ($R = 0.969$). The strong correlation between IC_{50} s and MICs observed in other bacterial species (Table 3 and Fig. 7) corroborated this notion. Although the properties of bacteria to incorporate drugs may have some influence on MICs, the quinolone-inhibited DNA supercoiling assay on recombinant *S. Typhimurium* DNA gyrase could be used as a quick test to screen drugs with promising antibacterial activities. Quinolones with IC_{50} s below 1 $\mu\text{g/ml}$ can potentially be active against *S. Typhimurium*. In contrast, quinolones with high IC_{50} s in the enzyme assay may not be suitable for further evaluation as antibacterial drugs. Additionally, the high similarity of the amino acid sequences of both the A and B subunits of DNA gyrase between the quinolone-susceptible typhoidal and non-typhoidal *Salmonella* strains enables the usage of recombinant *S. Typhimurium* DNA gyrase for the *in vitro* selection of quinolones not only against *S. Typhimurium*, but also against other *Salmonella* species including highly pathogenic serovers, *S. Typhi* and *S. Paratyphi A*.

In conclusion, we succeeded in expressing and purifying recombinant *S. Typhimurium* DNA gyrase, which is the primary target of quinolones in this particular microorganism. Based on measurements of the interaction between quinolones and purified *S. Typhimurium* DNA gyrase, we carried out two simple assays for the rapid investigation of the quinolone structure-activity relationship and screening of new quinolone derivatives for their anti-*S. Typhimurium* activities. The results of this study suggest that the *in vitro* quinolone-inhibited supercoiling assay may be a useful and predictive technique to monitor the antibacterial potency of quinolones.

Acknowledgements

This work was supported by a Department of Microbiology Grant; the China Medical Board; the Faculty of Public Health; Mahidol University; the National Development of Science and Technology, Ministry of Science and Technology, Bangkok, Thailand to OS; J-GRID; the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (MEXT); and the Global Center of Excellence (GCOE) Program, “Establishment of International Collaboration Centers for Zoonosis Control” from MEXT to YS.

326 REFERENCES

- 327 [1] S.E. Majowicz, J. Musto, E. Scallan, F.J. Angulo, M. Kirk, S.J. O'Brien, et al., The
328 global burden of nontyphoidal *Salmonella* gastroenteritis., *Clin. Infect. Dis.* 50 (2010)
329 882–9. doi:10.1086/650733.
- 330 [2] R.S. Hendriksen, A.R. Vieira, S. Karlsmose, D.M.A. Lo Fo Wong, A.B. Jensen, H.C.
331 Wegener, et al., Global monitoring of *Salmonella* serovar distribution from the World
332 Health Organization Global Foodborne Infections Network Country Data Bank: results
333 of quality assured laboratories from 2001 to 2007., *Foodborne Pathog. Dis.* 8 (2011)
334 887–900. doi:10.1089/fpd.2010.0787.
- 335 [3] C.Y. Meng, B.L. Smith, L. Bodhidatta, S.A. Richard, K. Vansith, B. Thy, et al.,
336 Etiology of diarrhea in young children and patterns of antibiotic resistance in
337 Cambodia., *Pediatr. Infect. Dis. J.* 30 (2011) 331–5.
338 doi:10.1097/INF.0b013e3181fb6f82.
- 339 [4] A.T.T. Vo, E. van Duijkeren, W. Gaastra, A.C. Fluit, Antimicrobial resistance, class 1
340 integrons, and genomic island 1 in *Salmonella* isolates from Vietnam., *PLoS One.* 5
341 (2010) e9440. doi:10.1371/journal.pone.0009440.
- 342 [5] W. Wannaprasat, P. Padungtod, R. Chuanchuen, Class 1 integrons and virulence genes
343 in *Salmonella enterica* isolates from pork and humans., *Int. J. Antimicrob. Agents.* 37
344 (2011) 457–61. doi:10.1016/j.ijantimicag.2010.12.001.
- 345 [6] L.-H. Su, C.-H. Chiu, C. Chu, J.T. Ou, Antimicrobial resistance in nontyphoid
346 *Salmonella* serotypes: a global challenge., *Clin. Infect. Dis.* 39 (2004) 546–51.
347 doi:10.1086/422726.
- 348 [7] K.L. Hopkins, R.H. Davies, E.J. Threlfall, Mechanisms of quinolone resistance in
349 *Escherichia coli* and *Salmonella*: recent developments., *Int. J. Antimicrob. Agents.* 25
350 (2005) 358–73. doi:10.1016/j.ijantimicag.2005.02.006.
- 351 [8] J.J. Champoux, DNA topoisomerases: structure, function, and mechanism., *Annu. Rev.*
352 *Biochem.* 70 (2001) 369–413. doi:10.1146/annurev.biochem.70.1.369.
- 353 [9] A. Cloeckaert, E. Chaslus-Dancla, Mechanisms of quinolone resistance in *Salmonella*.,
354 *Vet. Res.* 32 (n.d.) 291–300. doi:10.1051/vetres:2001105.
- 355 [10] J. Ruiz, Mechanisms of resistance to quinolones: target alterations, decreased
356 accumulation and DNA gyrase protection., *J. Antimicrob. Chemother.* 51 (2003)
357 1109–17. doi:10.1093/jac/dkg222.
- 358 [11] J. Heddle, A. Maxwell, Quinolone-binding pocket of DNA gyrase: role of GyrB.,
359 *Antimicrob. Agents Chemother.* 46 (2002) 1805–15.
360 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127264&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127264&tool=pmcentrez&rendertype=abstract)
361 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127264&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).

- 362 [12] H. Yoshida, M. Bogaki, M. Nakamura, L.M. Yamanaka, S. Nakamura, Quinolone
363 resistance-determining region in the DNA gyrase *gyrB* gene of *Escherichia coli*.,
364 *Antimicrob. Agents Chemother.* 35 (1991) 1647–50.
365 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=245234&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=245234&tool=pmcentrez&rendertype=abstract)
366 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=245234&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 367 [13] Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial
368 susceptibility tests for bacteria that grow aerobically; approved standard M7-A9, 9th
369 ed., Wayne, PA., 2006.
- 370 [14] S. Matrat, S. Petrella, E. Cambau, W. Sougakoff, V. Jarlier, A. Aubry, Expression and
371 purification of an active form of the *Mycobacterium leprae* DNA gyrase and its
372 inhibition by quinolones., *Antimicrob. Agents Chemother.* 51 (2007) 1643–8.
373 doi:10.1128/AAC.01282-06.
- 374 [15] H. Kim, C. Nakajima, K. Yokoyama, Z. Rahim, Y.U. Kim, H. Oguri, et al., Impact of
375 the E540V amino acid substitution in *GyrB* of *Mycobacterium tuberculosis* on
376 quinolone resistance., *Antimicrob. Agents Chemother.* 55 (2011) 3661–7.
377 doi:10.1128/AAC.00042-11.
- 378 [16] K. Yokoyama, H. Kim, T. Mukai, M. Matsuoka, C. Nakajima, Y. Suzuki, Amino acid
379 substitutions at position 95 in *GyrA* can add fluoroquinolone resistance to
380 *Mycobacterium leprae*., *Antimicrob. Agents Chemother.* 56 (2012) 697–702.
381 doi:10.1128/AAC.05890-11.
- 382 [17] K.E. Scheirer, N.P. Higgins, The DNA cleavage reaction of DNA gyrase. Comparison
383 of stable ternary complexes formed with enoxacin and CcdB protein., *J. Biol. Chem.*
384 272 (1997) 27202–9. <http://www.ncbi.nlm.nih.gov/pubmed/9341164> (accessed July 18,
385 2014).
- 386 [18] J.F. Barrett, J.I. Bernstein, H.M. Krause, J.J. Hilliard, K.A. Ohemeng, Testing potential
387 gyrase inhibitors of bacterial DNA gyrase: a comparison of the supercoiling inhibition
388 assay and “cleavable complex” assay., *Anal. Biochem.* 214 (1993) 313–7.
389 doi:10.1006/abio.1993.1493.
- 390 [19] F. Blanche, B. Cameron, F.X. Bernard, L. Maton, B. Manse, L. Ferrero, et al.,
391 Differential behaviors of *Staphylococcus aureus* and *Escherichia coli* type II DNA
392 topoisomerases., *Antimicrob. Agents Chemother.* 40 (1996) 2714–20.
393 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163609&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163609&tool=pmcentrez&rendertype=abstract)
394 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163609&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 395 [20] X.S. Pan, L.M. Fisher, Targeting of DNA gyrase in *Streptococcus pneumoniae* by
396 sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.,
397 *Antimicrob. Agents Chemother.* 41 (1997) 471–4.
398 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163733&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163733&tool=pmcentrez&rendertype=abstract)
399 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163733&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 400 [21] J. Han, Y. Wang, O. Sahin, Z. Shen, B. Guo, J. Shen, et al., A fluoroquinolone
401 resistance associated mutation in *gyrA* Affects DNA supercoiling in *Campylobacter*
402 *jejuni*., *Front. Cell. Infect. Microbiol.* 2 (2012) 21. doi:10.3389/fcimb.2012.00021.

- 403 [22] A. Aubry, X.-S. Pan, L.M. Fisher, V. Jarlier, E. Cambau, Mycobacterium tuberculosis
404 DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug
405 activity., *Antimicrob. Agents Chemother.* 48 (2004) 1281–8.
406 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=375300&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=375300&tool=pmcentrez&rendertype=abstract)
407 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=375300&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 408 [23] M. Nakatani, S. Mizunaga, M. Takahata, N. Nomura, Inhibitory activity of
409 garenoxacin against DNA gyrase of *Mycoplasma pneumoniae*., *J. Antimicrob.*
410 *Chemother.* 67 (2012) 1850–2. doi:10.1093/jac/dks140.
- 411 [24] L.R. Peterson, Quinolone molecular structure-activity relationships: what we have
412 learned about improving antimicrobial activity., *Clin. Infect. Dis.* 33 Suppl 3 (2001)
413 S180–6. doi:10.1086/321846.
- 414 [25] G.S. Tillotson, Quinolones: structure-activity relationships and future predictions., *J.*
415 *Med. Microbiol.* 44 (1996) 320–4. <http://www.ncbi.nlm.nih.gov/pubmed/8636945>
416 (accessed July 27, 2014).
- 417 [26] S. Emami, A. Shafiee, A. Foroumadi, Quinolones: Recent Structural and Clinical
418 Developments, *Iran. J. Pharm. Res.* (2010) 123–136.
419 http://ijpr.sbm.ac.ir/article_628_0.html (accessed July 27, 2014).
- 420 [27] H. Yoshida, M. Bogaki, M. Nakamura, S. Nakamura, Quinolone resistance-
421 determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*., *Antimicrob.*
422 *Agents Chemother.* 34 (1990) 1271–2.
423 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171799&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171799&tool=pmcentrez&rendertype=abstract)
424 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171799&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 425 [28] I. Guillemain, W. Sougakoff, E. Cambau, V. Revel-Viravau, N. Moreau, V. Jarlier,
426 Purification and inhibition by quinolones of DNA gyrases from *Mycobacterium avium*,
427 *Mycobacterium smegmatis* and *Mycobacterium fortuitum* bv. *peregrinum*.,
428 *Microbiology.* 145 (Pt 9 (1999) 2527–32.
429 <http://www.ncbi.nlm.nih.gov/pubmed/10517605> (accessed July 18, 2014).
- 430 [29] G. Yague, J.E. Morris, X.-S. Pan, K.A. Gould, L.M. Fisher, Cleavable-complex
431 formation by wild-type and quinolone-resistant *Streptococcus pneumoniae* type II
432 topoisomerases mediated by gemifloxacin and other fluoroquinolones., *Antimicrob.*
433 *Agents Chemother.* 46 (2002) 413–9.
434 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127068&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127068&tool=pmcentrez&rendertype=abstract)
435 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127068&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 436 [30] I. Guillemain, E. Cambau, V. Jarlier, Sequences of conserved region in the A subunit of
437 DNA gyrase from nine species of the genus *Mycobacterium*: phylogenetic analysis and
438 implication for intrinsic susceptibility to quinolones., *Antimicrob. Agents Chemother.*
439 39 (1995) 2145–9.
440 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162899&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162899&tool=pmcentrez&rendertype=abstract)
441 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162899&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).
- 442 [31] L. Walton, L.P. Elwell, In vitro cleavable-complex assay to monitor antimicrobial
443 potency of quinolones., *Antimicrob. Agents Chemother.* 32 (1988) 1086–9.

444 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172350&tool=pmcentrez&](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172350&tool=pmcentrez&rendertype=abstract)
445 [rendertype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172350&tool=pmcentrez&rendertype=abstract) (accessed July 18, 2014).

446 [32] V. Jarlier, H. Nikaido, Mycobacterial cell wall: structure and role in natural resistance
447 to antibiotics., FEMS Microbiol. Lett. 123 (1994) 11–8.
448 <http://www.ncbi.nlm.nih.gov/pubmed/7988876> (accessed July 18, 2014).

449

450

TABLE 1 Oligonucleotide sequences of primers used for PCR

Primer name	Sequence (nucleotide position)	Comment
ST1	5'-ggcatatgagcgaccttgcgagaga-3' (1-20), NdeI site	Wildtype <i>gyrA</i>
ST2	5'-ggctcgagctcgtcagcgatccgc-3' (2617-2634), XhoI site	Wildtype <i>gyrA</i>
ST8	5'-ggcatatgtcgaattcttatgactc-3' (1-20), NdeI site	Wildtype <i>gyrB</i>
ST9	5'-ggctcgagaatatcgatattcgctgcttc-3' (2391-2412), XhoI site	Wildtype <i>gyrB</i>

451

452

TABLE 2 Structural features, minimum inhibitory concentration and concentration of quinolones inhibiting *S. Typhimurium* wildtype gyrase activity

Quinolone	R-1	R-6	R-7	R-8	IC ₅₀ (µg/ml)	CC ₂₅ (µg/ml)	MIC (µg/ml)
SIT	fluorinated cyclopropyl	F	pyrrolidine	Cl	0.22 ± 0.04	0.24 ± 0.05	0.0078
CIP	cyclopropyl	F	piperazine	H	0.25 ± 0.05	0.31 ± 0.10	0.0078
GAT	cyclopropyl	F	piperazine	O-CH ₃	0.30 ± 0.05	0.30 ± 0.03	0.0625
SPX	cyclopropyl	F	piperazine	F	0.42 ± 0.04	0.69 ± 0.14	0.0625
LVX	bridge C1-C8	F	piperazine	bridge C1-C8	0.43 ± 0.03	0.31 ± 0.03	0.0625
MXF	cyclopropyl	F	azabicyclo	O-CH ₃	0.48 ± 0.01	0.34 ± 0.13	0.0625
ENR	cyclopropyl	F	piperazine	H	0.57 ± 0.03	0.86 ± 0.24	0.0625
OFX	bridge C1-C8	F	piperazine	bridge C1-C8	0.69 ± 0.20	0.67 ± 0.13	0.0625
OXO	ethyl	H	bridge C6-C7	H	4.93 ± 1.54	3.40 ± 0.75	0.5
NAL	ethyl	H	CH ₃	N	65.1 ± 19.08	8.64 ± 0.38	4

458 **TABLE 3 IC₅₀s (μ g/ml) and MIC₅₀s (μ g/ml) for different bacterial species**

Quinolone	<i>S. Typhimurium</i> ^a		<i>E. coli</i> ^b		<i>M. tuberculosis</i> ^c		<i>S. pneumoniae</i> ^d		<i>M. pneumoniae</i> ^e	
	IC ₅₀ s	MICs	IC ₅₀ s	MICs	IC ₅₀ s	MICs	IC ₅₀ s	MICs	IC ₅₀ s	MICs
SIT	0.22	0.0078			2.5	0.25				
CIP	0.25	0.0078	0.3	0.007	3.5	0.5	40	1-2		
GAT	0.30	0.0625			3	0.12	20-40	0.25	5.71	0.125
SPX	0.42	0.0625	0.2	0.015	2	0.25				
LVX	0.43	0.0625	0.29	0.015	5	0.5	80	1	47.5	0.5
MXF	0.48	0.0625			4.5	0.5	20	0.25	7.44	0.0625
ENR	0.57	0.0625								
OFX	0.69	0.0625	0.35	0.03	10	1				
OXO	4.93	0.5			300	32				
NAL	65.1	4	50	2	1100	128				

^aThis work

^bReference 28

^cReference 22

^dReference 29

^eReference 23

459

460

FIGURE LEGENDS

Figure 1. SDS-PAGE analysis of recombinant DNA gyrase subunits of *S. Typhimurium*.

His-tagged proteins were overexpressed by an *E. coli* expression system and purified by nickel resin chromatography. Each protein sample (approximately 3 μ M) was loaded in a SuperSepTMAce 5-20% gradient gel. Following electrophoresis, proteins were revealed by Quick CBB staining. Lane M, size markers (sizes are indicated to the left in kilodaltons); lane 1, wildtype GyrA subunit; lane 2, wildtype GyrB subunit.

Figure 2. Wildtype GyrA and wildtype GyrB proteins of *S. Typhimurium* generate

ATP-dependent DNA supercoiling activity. Relaxed pBR322 DNA (0.3 μ g) was incubated with mutant DNA gyrase reconstituted from wildtype (WT) GyrA (3 μ M) and WT GyrB (3 μ M) in the presence or absence of 1 mM ATP. The reactions were stopped, and the DNA products were separated by electrophoresis in 1% agarose gels. DNA was stained with ethidium bromide and photographed under UV illumination. Lanes 1, relaxed pBR322 DNA; lane 2, relaxed pBR322 DNA and both recombinant WT GyrA and WT GyrB proteins; lane 3, relaxed pBR322 DNA and only GyrA protein; lane 4, relaxed pBR322 DNA and mutants GyrB protein; lane 5, absence of ATP. R and SC are indicated relaxed and supercoiled pBR322 DNA, respectively.

Figure 3. Inhibitory activities of CIP and NAL on the supercoiling activities of *S.*

Typhimurium DNA gyrase. Relaxed pBR322 DNA (0.3 μ g) was incubated with each DNA gyrase subunit (3 μ M) in the presence of the indicated amounts (μ g ml⁻¹) of CIP and NAL. The reactions were stopped, and the DNA products were analyzed by electrophoresis in 1% agarose gels. R and SC denote relaxed and supercoiled pBR322 DNA, respectively.

Figure 4. CIP- and NAL-mediated DNA cleavage assay by DNA gyrase of *S.*

Typhimurium. Supercoiled pBR322 DNA (0.3 μ g) was incubated with DNA gyrase (3 μ M) in the presence of the indicated amounts (μ g ml⁻¹) of CIP and NAL. After the addition of SDS

486 and protease K, the reactions were stopped and the mixtures were analyzed by electrophoresis
487 in 0.8% agarose gels. R, L and SC denote relaxed, BamHI-linearized and supercoiled
488 pBR322 DNA, respectively.

489 **Figure 5.** Correlation between the antibacterial activity (MICs) of quinolones and the
490 corresponding concentration of quinolones inhibiting the supercoiling activity (IC_{50} values)
491 of DNA gyrases from *S. Typhimurium* (R = correlation coefficient value).

492 **Figure 6.** Correlation between the antibacterial activity (MICs) of quinolones and the
493 corresponding concentration of quinolones inducing cleavable complex formation (CC_{25}
494 values) of DNA gyrases from *S. Typhimurium* (R = correlation coefficient value).

495 **Figure 7.** Alignment of amino acid sequences of GyrA QRDR for 5 bacterial species.

496 **Supplementary Figure 1. Inhibitory activities of a) SIT, b) GAT, c) SPX, d) LVX, e)**
497 **MXF, f) ENR, g) OFX, and h) OXO on the supercoiling activities of *S. Typhimurium***
498 **wildtype DNA gyrases.** Relaxed pBR322 DNA (0.3 μg) was incubated with DNA gyrase (3
499 μM) in the presence of the indicated amounts ($\mu\text{g ml}^{-1}$) of the respective quinolones. The
500 reactions were stopped, and the DNA products were analyzed by electrophoresis in 1%
501 agarose gels. R and SC denote relaxed and supercoiled pBR322 DNA, respectively.

502 **Supplementary Figure 2. Quinolone-mediated DNA cleavage assay of a) SIT, b) GAT, c)**
503 **SPX, d) LVX, e) MXF, f) ENR, g) OFX, and h) OXO on the DNA gyrases of *S.***
504 ***Typhimurium*.** Supercoiled pBR322 DNA (0.3 μg) was incubated with each WT DNA
505 gyrase (3 μM) in the presence of the indicated amounts ($\mu\text{g ml}^{-1}$) of the respective
506 quinolones. After the addition of SDS and protease K, the reactions were stopped and the
507 mixtures were analyzed by electrophoresis in 0.8% agarose gels. R, L and SC denote relaxed,
508 BamHI-linearized and supercoiled pBR322 DNA, respectively.

Kongsoi *et al.* Figure 1

Figure 2

Kongsoi *et al.* Figure 3

Kongsoi *et al.* Figure 4

Kongsoi *et al.* Figure 5

Kongsoi *et al.* Figure 6

Correlation between quinolone inhibition of *C. jejuni* gyrase (IC_{50} s for DNA supercoiling) and quinolone MICs for *C. jejuni*. R is the correlation coefficient. SIT, sitafloxacin; GAT, gatifloxacin; MXF, moxifloxacin; SPX, sparfloxacin; ENR, enrofloxacin; CIP, ciprofloxacin; LVX, levofloxacin; OFX, ofloxacin; OXO, oxolinic acid; NAL, nalidixic acid.